Biology Atlas

Map / Open register

question · intermediate · partly written

Why did tominersen make patients worse while lowering mutant huntingtin?

In GENERATION HD1 the antisense drug lowered mutant huntingtin in the spinal fluid, yet the every-2-months arm did worse than placebo and dosing was halted; the cause is not established.

The lesson in brief

Lowering the target protein is a measurement that the drug works, not that the patient benefits. See drugs/tominersen for the sourced numbers. 123

Reported, not yet replicated

Observation

Roche summary of GENERATION HD1: dosing was halted in March 2021 on an independent committee advice and the every-2-months arm was clinically worse than placebo at week 69, although mutant huntingtin in the spinal fluid fell. See drugs/tominersen for the numbers. 123

Reported, not yet replicated

Hypotheses

Dose-linked toxicity or inflammation

Higher exposure caused harm unrelated to huntingtin lowering. 2

Predicts. Harm should track exposure.

Would falsify. Harm not related to exposure or dose.

Our inference

Disease too advanced for the lowering to help

Lowering the protein in people with more damage could not reverse loss. 2

Predicts. Benefit in earlier-stage patients.

Would falsify. No benefit even at the earliest stage.

Our inference

What is missing

Why exposure and outcome did not track

The cause of the worse outcome has not been shown in the opened sources; secondary explainers list hypotheses only. 12

Our inference

What is known

Mutant huntingtin fell, a marker of neuron injury rose in the every-2-months arm, and the arm did worse than placebo. 123

Reported, not yet replicated

What is not

Whether the harm came from the drug, its dose, its chemistry or the disease stage. 123

Contested

What would settle it

Further analyses and later trials that vary dose and disease stage. 123

Our inference

Still open here

Not yet written: Who works on it.

Sources

  1. F. Hoffmann-La Roche Ltd (sponsor). GENERATION HD1 (BN40423) final results: plain-language summary, September 2023. Roche forpatients (2023). organisation-page, not peer reviewed; opened 2026-11-17 all records citing this
  2. HDBuzz. HDBuzz explainer on the GENERATION HD1 results (article 354). HDBuzz (patient-community science news) (2023). news, not peer reviewed; opened 2026-11-17 all records citing this
  3. BioSpace. Ionis and Roche halt Huntington's disease trials. BioSpace (2021). news, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (1)

This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Kind
big-open
Register
open-question
Triage
needs-research
Status
partly written
Last updated
2026-11-17
Record
content/questions/why-did-tominersen-fail-despite-lowering-huntingtin.json